Kane Biotech Announces Granting of Options
April 17 2019 - 4:15PM
Kane Biotech Inc. (TSX-V:KNE), (the “Corporation” or “Kane
Biotech”), a biotechnology company engaged in the research,
development and commercialization of technologies and products that
prevent and remove microbial biofilms, today announces that it has
granted an aggregate of 1,775,000 stock options at an exercise
price of $0.10 per common share to directors, management, employees
and consultants of the Corporation. The grant date of these stock
options is October 23, 2018.
The options pursuant to the Corporation's stock option plan are
subject to TSX Venture Exchange acceptance. In accordance with
securities regulatory requirements, any shares issued pursuant to
the exercise of such options will be subject to resale restriction
for a period of four months from the date of the grant.
About Kane Biotech Kane Biotech is a
biotechnology company engaged in the research, development and
commercialization of technologies and products that prevent and
remove microbial biofilms. The Corporation has a portfolio of
biotechnologies, intellectual property (66 patents and patents
pending, trade secrets and trademarks) and products developed by
the Corporation’s own biofilm research expertise and acquired from
leading research institutions. StrixNB(TM), DispersinB(R),
Aledex(R), bluestem(TM), AloSera(TM), coactiv+(TM) and
Kane(R) are trademarks of Kane Biotech Inc. The Corporation is
listed on the TSX Venture Exchange under the symbol "KNE".
For more information, please visit
www.kanebiotech.com or contact: |
|
Marc Edwards |
|
Chief Executive Officer |
|
Kane Biotech Inc. |
|
+1 (514) 910-6991 |
medwards@kanebiotech.com |
|
|
Grant Humphrey |
|
Vice President, Sales and Business
Development |
|
Kane Biotech Inc. |
|
+1 (204) 914-5089 |
ghumphrey@kanebiotech.com |
|
|
Joe Green |
|
US. Investor Relations |
|
Edison Inc. |
|
+1 (646) 653-7030 |
jgreen@edisongroup.com |
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
Caution Regarding Forward-Looking Information
This press release contains certain statements regarding Kane
Biotech Inc. that constitute forward-looking information under
applicable securities law. These statements reflect management’s
current beliefs and are based on information currently available to
management. Certain material factors or assumptions are applied in
making forward-looking statements, and actual results may differ
materially from those expressed or implied in such statements.
These risks and uncertainties include, but are not limited to,
risks relating to the Company’s: (a) financial condition, including
lack of significant revenues to date and reliance on equity and
other financing; (b) business, including its early stage of
development, government regulation, market acceptance for its
products, rapid technological change and dependence on key
personnel; (c) intellectual property including the ability of the
Company to protect its intellectual property and dependence on its
strategic partners; and (d) capital structure, including its lack
of dividends on its common shares, volatility of the market price
of its common shares and public company costs. Further information
about these and other risks and uncertainties can be found in the
disclosure documents filed by the Company with applicable
securities regulatory authorities, available at www.sedar.com. The
Company cautions that the foregoing list of factors that may affect
future results is not exhaustive.
Kane Biotech (TSXV:KNE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Kane Biotech (TSXV:KNE)
Historical Stock Chart
From Apr 2023 to Apr 2024